Integrative genomic, transcriptomic, and epigenomic analyses of benign prostatic hyperplasia reveal new options for therapy
Deli Liu, Jonathan Evan Shoag, Daniel Poliak, Ramy S. Goueli, Vaishali Ravikumar, David Redmond, Aram Vosoughi, Jacqueline Fontugne, Heng Pan, Daniel C. Lee, Domonique Thomas, Keyan Salari, Zongwei Wang, Alessandro Romanel, Alexis E. Te, , Christopher E. Barbieri
This study identifies molecular subgroups of BPH and suggests mTOR inhibitors as a potential therapy for specific subtypes.
bioRxiv · Oct 16, 2019 · PreprintGenomics